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"Education is not the learning of facts, but the training 
of the mind to think" 
Albert Einstein 
  
  
ABSTRACT 
Elevated plasma LDL-C is today considered a causative factor for the development of 
atherosclerosis. Increased plasma LDL-C levels are mainly due to reduced numbers of 
functional LDL receptors (LDLRs) in the liver. PCSK9 and IDOL, are two, recently 
identified key regulators of cholesterol metabolism, both reducing LDLR numbers in the liver 
and peripheral tissue thereby increasing plasma LDL-C levels.  Several hormones such as 
estrogen, testosterone and ACTH are known to influence lipoprotein metabolism. In addition, 
bile acids such as CDCA have been reported to modulate cholesterol metabolism. However, 
little is known about the underlying mechanisms behind these effects.    
In this study, we investigated how natural changes of the endogenous levels of estrogen and 
how treatments with testosterone, ACTH, and with the natural FXR agonist (CDCA) 
influence cholesterol metabolism, with a particular focus on the role of PCSK9. It is 
concluded that: 
1) The natural changes of estrogen levels during the menstrual cycle correlate to the 
concomitant changes observed in circulating levels of PCSK9 and LDL-C. Further, 
after menopause PCSK9 levels and plasma LDL-C increase while in ageing men of 
similar age PSCK9 levels were stable.   
2) High dose testosterone treatment reduces PCSK9 levels, indicating that this LDLR 
modulator is under hormonal control. However, the known gender differences in bile 
acid and cholesterol synthesis cannot be explained from testosterone levels in human.  
3) The adrenal glands are practically devoid of the PCSK9 protein while instead IDOL 
is expressed. Treatment with ACTH suppresses adrenal IDOL expression 
contributing to the powerful increase in LDLR number during severe stress. 
Simultaneously, the number of hepatic LDLRs is reduced through a posttrascriptional 
increase of PCSK9 protein. This effect is dependent on the presence of intact adrenals, 
compatible with the concept that a sustained adrenal production of corticosteroids is 
secured by shunting LDL-C to the adrenals in situations of severe stress. 
4) CDCA influences lipid metabolism by reducing plasma clearance of LDL-C. The 
reduction of circulating PCSK9 by CDCA treatment may counter-balance its effect 
on hepatic LDLRs and plasma LDL-cholesterol.  
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1. INTRODUCTION 
In humans, an increased risk for development of atherosclerosis and cardiovascular events is 
associated with disturbances in cholesterol metabolism. Epidemiological studies have 
demonstrated that LDL cholesterol (LDL-C), age, gender, blood pressure, diabetes, smoking, 
obesity, family history, and an unhealthy diet are important risk factors for atherosclerosis. 
In humans, LDL cholesterol is now considered a causative factor for the development of 
arteriosclerosis. (1, 2).  
Cholesterol metabolism can be altered by several factors. Hormones such as estrogen, thyroid 
hormone (TH), adrenocorticotropic hormone (ACTH), and growth hormone (GH) have been 
reported to influence cholesterol homeostasis (3-8). Proteins such as the low-density 
lipoprotein receptor (LDLR), sterol regulatory element-binding protein 2 (SREBP2), 
proprotein convertase subtilisin/kexin type 9 (PCSK9) and apolipoprotein B (ApoB) play 
crucial roles in cholesterol metabolism (9). Moreover, environmental factors such as diet and 
life style are important for cholesterol metabolism.  
1.1 Cholesterol metabolism 
Cholesterol is of fundamental importance for normal cell function and serves as a precursor 
in the synthesis of bile acids and of steroid hormones such as estrogens, testosterone, and the 
glucocorticoids. Cells acquire cholesterol by de novo synthesis (endogenous pathway) and 
from the diet (exogenous pathway).  
Endogenous pathway: Although all nucleated cells can produce cholesterol, the liver and 
intestine play the primary role in cholesterol synthesis in humans and animals. 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCoAR) is the rate-limiting enzyme in 
cholesterol synthesis. HMGCoAR is an integral membrane protein, which is regulated via 
negative feedback mechanism through the SREBP pathway. When intracellular cholesterol 
is low, SREBP2 is activated by cleavage and translocated to the nucleus where it initiates the 
transcription of HMGCoAR (1, 2). When cholesterol is in excess within cells, SREBP2 is 
inactivated which negatively regulates cholesterol synthesis (10, 11). Cholesterol synthesis 
has a diurnal rhythm that peaks at midnight (10). Statins, the most commonly used lipid-
lowering drugs bind strongly to the HMGCoAR protein thereby inactivating the enzyme 
activity. (12).  
Exogenous pathway: After food intake, dietary lipids are hydrolyzed by pancreatic lipases 
and form micelles with bile acids that are absorbed by brush border membrane of enterocytes 
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(13). Cholesterol enters the brush border membranes either via different transporters such as 
Niemann-Pick C1 Like 1 (NPC1L1) (14), or by passive diffusion, and is then re-esterified by 
acetyl-Coenzyme A acetyltransferase 2 (ACAT2) (15). Whereas ATP-binding cassette 
transporters G5 and G8 (ABCG5/8) preferentially pump out plant sterols, they also help to 
transport back absorbed cholesterol into the intestinal lumen (16-18). Within the enterocyte, 
esterified sterol assembles with triglycerides (TGs) and apolipoproteins in the presence of 
microsomal triglyceride transfer protein (MTTP) and promotes lipoprotein formation. 
Lipoproteins such as Chylomicrons and VLDL reach the circulation from the enterocyte via 
the lymphatic system (Fig 1) (19, 20).  
1.2   Lipoprotein metabolism 
Lipoproteins are classified into five classes: chylomicrons, very low-density lipoprotein 
(VLDL), intermediate density lipoprotein (IDL), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) (21-27) (Table 1). High amounts of plasma cholesterol, especially 
LDL-C and VLDL-cholesterol (VLDL-C), as well as low levels of HDL-cholesterol (HDL-
C) are linked to CVD. Moreover, subclasses of lipoproteins such as Lipoprotein (a) (Lp(a)) 
may also be atherogenic.   
Chylomicrons  
Chylomicrons are the largest lipoproteins and are formed postprandially in the enterocytes. 
They deliver FFAs to peripheral tissues in a similar way as VLDL particles are then removed 
by LDLRs or by LDLR-related proteins (LRP) in the liver (27).  
VLDL 
Nascent VLDL particles, are secreted from the liver and contain ApoB100, apolipoprotein 
C1 (ApoC1) and apolipoprotein E (ApoE). In the circulation, they pick up apolipoprotein C-
II (ApoC-II) and additional apoE, forming mature VLDL. These particles are then hydrolyzed 
by LPL to release free fatty acids (FFA) which are taken up by peripheral tissues. Thereafter, 
VLDL remnant (IDL) particles are either cleared by LDLRs or metabolized into LDL by 
hepatic lipase (HL) (25, 26).  
IDL 
IDL is the intermediate density lipoprotein between LDL and VLDL. IDL is produced from 
the degradation of the larger, triglyceride-rich VLDL. However, it is quickly cleared from 
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circulation. Either hepatic LDLRs remove the IDL particle from the circulation or it is 
converted to LDL moieties (24).  
LDL 
LDL particles are formed from IDL and deliver cholesterol to cells by LDLR-mediated 
endocytosis. LDLs can also be taken up by macrophages and initiate the atherogenic process. 
To reduce the risk of CVD by lowering LDL-C is a primary target of lipid lowering therapy 
(23).  
 
HDL 
An important function of HDL is to transport cholesterol from peripheral tissues to liver a 
pathway designated reverse cholesterol transport. HDL removes excess cholesterol during 
the process called "HDL biogenesis" which occurs through a complex pathway that involves 
the lipid transporter ATP-binding cassette A1 (ABCA1) and the plasma enzyme lecithin 
cholesterol acyl transferase (LCAT). Although a high plasma level of HDL seems to protect 
Table 1: Major lipoproteins and their characteristics. 
 
Lipoproteins Density 
(g/mL) 
Diameter 
(nm) 
TG 
% 
Chol 
% 
PL 
 % 
Protein 
% 
Half- 
life 
Surface  
Apolipoproteins 
Chylomicron 0.93 75-1200 80-95 2-5 3-8 1-2 15 min ApoB48, ApoAI, ApoAII, 
ApoAIV, ApoCII and ApoE.  
VLDL 0.93-1.006 30-80 50 22 19 8 2 h ApoB100, ApoC, ApoE 
IDL 1.006-1.019 25-35 20 38 23 19 2-6 h ApoB100 and ApoE 
LDL 1.019-1.063 18-25 11 47 22 21 2-3 d ApoB100 
HDL 1.063-1.21 5-12 6 15-22 23-30 55 2-3 d ApoAI, ApoAII, ApoAIV, 
ApoC ApoE 
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against cardiovascular events, clinical trials where HDL has been pharmacologically 
increased have failed to reduce such events (21, 22).   
 
 
Fig1: Schematic diagram of cholesterol and lipoprotein metabolism.  
Dietary cholesterol (DC); Biliary cholesterol (BC): Plant sterol (PS) 
 
Lp(a) 
Lp(a) is  an LDL particle with an apo(a) molecule covalently bound to ApoB. The level of 
Lp(a) is highly influenced by polymorphisms of the Apo(a) gene and is linked to the risk for 
CVD. Since Apo(a) is expressed in liver cells, Lp(a) is believed to be synthesized in the 
hepatocyte where Apo(a) assembles with LDL. LDLRs may partially be involved in the 
plasma clearance of Lp(a), but the metabolism of Lp(a) is incompletely understood. The half-
life of Lp(a) is 3-4 days which is longer than LDL. The kidneys are also considered to play 
an important role in Lp(a) clearance from plasma (28-31). 
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Apolipoproteins 
Apolipoproteins are the protein part of lipoproteins, synthesized in liver or intestine. 
Apolipoproteins together with phospholipid and free cholesterol surround the lipid particles. 
Apolipoproteins work as ligands for various receptors or as activators of enzymes, 
influencing the cellular uptake of lipoprotein particles. Apolipoproteins are mainly classified 
into six groups with several sub-groups. These are Apo A (Apo AI, Apo AII, Apo AIV and 
Apo AV), Apo B (Apo B48 and Apo B100), Apo C (Apo CI, Apo CII, Apo CIII and Apo 
CIV), Apo D, Apo E, Apo H and Apo L.  
1.3   Bile acid metabolism 
Bile acids are derivatives of cholesterol produced in the liver. Every day, about 500mg 
cholesterol, is converted to bile acids. Previously bile acids were mainly considered as 
detergents, facilitating lipid absorption, but studies have established several other important 
functions. 
Primary bile acids  
Bile acids are synthesized through a "classical" and an "alternative" pathways. Cholic acid 
(CA) and chenodeoxycholic acid (CDCA) are the two primary bile acids in humans, and 90% 
of bile acids are formed by the classical pathway. Cholesterol 7alpha-hydroxylase 
(CYP7A1), a member of the cytochrome P450 superfamily, is the rate-limiting enzyme for 
the classic pathway. Cholesterol is hydroxylated by CYP7A1 and then metabolized to 7α-
hydroxy-4-cholesten-3-one (C4) by 3β-hydroxysteroid hydrogenase (HSD3B7). C4 serves 
as a precursor for CA and CDCA. Therefore, serum C4 levels can be used as a marker for 
bile acid synthesis (32, 33) (Fig 2).  
Secondary bile acids 
About 5% of bile acids that enter the gut escape absorption in the small intestine, to enter the 
large intestine where they are dehydroxylated into secondary bile acids by bacteria. In 
humans and rodents, deoxycholic acid (DCA), lithocholic acid (LCA) and small amounts of 
ursodeoxycholic acid (UDCA) are produced as secondary bile acids. These secondary bile 
acids are then either passively absorbed and resecreted or excreted in feces (34, 35). 
Enterohepatic circulation 
Bile acids circulate in the enterohepatic system several times after a meal. After food intake, 
the gallbladder contracts and empties bile into the gut where they contribute to micelle  
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 Fig 2: Bile acid synthesis (classical and alternative pathway) 
(AKR1C4: 3α-hydroxy steroid dehydrogenase 
AKR1D1: Oxosteroid-5β-reductase 
CYP7A1: Cholesterol 7α-hydroxylase 
CYP8B1: Sterol-12α-hydroxylase 
CYP27A1: Sterol 27-hydroxylase 
HSD3B7: 3β-hydroxy steroid dehydrogenase) 
 
formation and fat absorption. In the distal ileum, ASBT mediates the absorption of bile acids 
(about 95%) by the enterocytes.Thereafter bile acids are exported via organic solute 
transporters (OSTs) into the blood and transported back to the liver in the portal vain (36, 
37).The hepatocytes extract bile acids from portal blood, driven by sodium-taurocholate co-
transporting polypeptide (NTCP). In the liver, bile acids bind to Farnesoid X receptors (FXR) 
and suppress bile acid synthesis by down-regulating CYP7A1 (Fig 3). Primary bile acids 
such as CDCA and CA are natural FXR agonists that suppress bile acid synthesis by 
inhibiting CYP7A1 (38, 39). Another mechanism for feedback regulation of bile acid 
synthesis involves fibroblast growth factor 19 (FGF19) [fibroblast growth factor 15 (FGF15) 
in rodents]. This protein is secreted from enterocytes and transported to the liver where it 
binds to the FGF receptor 4 (FGFR4) which then down-regulates the expression of CYP7A1, 
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resulting in suppression of bile acid synthesis (40). Although FGF19 is detectable in the 
human circulation, the presence of plasma FGF15 in the rodent is controversial. However, a 
recent study has claimed that FGF15 is present in mouse serum (41).  
 
 
 
 Fig 3: Schematic diagram of bile acid metabolism 
 
1.4   LDLR 
LDLRs are found in all mammalian cells but at highest density in the adrenal gland. The liver 
expresses a major part of all LDLRs (42, 43). The LDLR is a five-domain membrane-bound 
glycoprotein, which is synthesized in the endoplasmic reticulum and transported to the cell 
membrane via the Golgi complex. LDLRs bind to both ApoB100 and ApoE, , the affinity 
being higher for ApoE (44). LDLRs bind and internalize LDL particles and promote their 
lysosomal degradation (45, 46). Mutations in the LDLR gene, located on chromosome 19, 
are the most frequent cause of familial hypercholesterolemia (FH) (47, 48). 
LDLR is transcriptionally regulated by SREBP2 (49). However, several recent studies have 
established the importance of post-transcriptional regulation of LDLR. Proprotein convertase 
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subtilisin/kexin type 9 (PCSK9) and Inducible Degrader of the LDL receptor (IDOL) are two 
such molecules, which can modulate the degradation of LDLRs (50).  
1.5   PCSK9  
PCSK9, the ninth member of the proprotein convertase family, is also known as neural 
apoptosis-regulated convertase 1. It was discovered in 2003 (51, 52). PCSK9 is abundant in 
the liver, and also found in the small intestine, kidney, and the central nervous system. In 
humans, the PCSK9 gene is located on chromosome 1p32.3 (53). Variants of this gene result 
in abnormal cholesterol metabolism. Gain of function (GOF) mutations lead to 
hypercholesterolemia, whereas loss of function (LOF) variants cause hypocholesterolemia 
and reduced risk of CVD (54). Several studies have established clear correlations between 
PCSK9 and cardiovascular complications (51-53).  
PCSK9 is secreted from the liver. Its precursor (72 Kda) is synthesized in the hepatocyte and 
produces a pro-segment and mature PCSK9 (63 KDa) via autocatalytic cleavage (55). Mature 
PCSK9 undergoes trafficking from ER to Golgi before secretion into the circulation (54, 55). 
Some post-translational modifications such as N-glycosylation, sulphation, and 
phosphorylation can take place before its secretion (53). The catalytic domain of circulating 
PCSK9 binds with the epidermal growth factor precursor homology domain-A (EGF-A) of 
the LDLR to form a LDLR/PCSK9 complex (56). This complex is then internalized via 
clathrin-mediated endocytosis (57) and is directed to the lysosome for degradation (57-60) 
(Fig 4). Recent studies have shown that intracellular PCSK9 can also promote LDLR 
degradation by binding to the LDLRs inside the cells (Fig 4) (54, 61). 
Regulators of PCSK9 
Several physiological and pharmacological parameters regulate the PCSK9 level and 
function. Physiological parameters such as age, gender and hormones have been proposed to 
be important in the regulation of PCSK9. Higher levels of circulating PCSK9 are found in 
females than in males. While pre-menopausal females have lower PCSK9 level than males, 
the level increases after menopause. In males, the level is quite stable throughout life (62, 
63). Moreover, it has been reported that various parameters such as LDL-C, total-C, 
triglycerides, insulin, body mass index (BMI), and glucose are positively correlated with 
plasma PCSK9 levels. Hormones such as estrogen, thyroid hormone, and glucagon have been 
reported to regulate PCSK9 as well. Diet has also been shown to be important for regulation 
of PCSK9 in animals and humans. Sterols affect PCSK9 mRNA expression via SREBP2 
pathway (64, 65). Mediterranean diet and food rich in polyunsaturated fatty acids (PUFAs) 
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reduce circulating PCSK9 in humans (66-68). Moreover, PCSK9 follows a diurnal rhythm in 
humans (69, 70).  
 
 
Fig 4: PCSK9 (intracellular and circulating) inhibits cellular uptake of LDL-C by degrading 
LDLR 
PCSK9 as a therapeutic target 
A decade of research has established that lowering of circulating and intracellular PCSK9 is 
a promising therapeutic approach for the treatment of dyslipidemia (53, 55, 62). Additionally, 
the commonly used lipid-lowering drugs such as statins and ezetimibe induce PCSK9 in 
humans to dampen their therapeutic effects. Inhibition of PCSK9 either by monoclonal 
antibodies or by molecules such as siRNA, peptides and small molecules are now undergoing 
clinical trials in different phases (71). 
1.6   IDOL 
IDOL, also known as Myosin regulatory light chain interacting protein (MYLIP), is a 
recently identified protein reported to regulate cholesterol homeostasis independent of 
SREBP pathway. Studies have demonstrated that loss-of-function mutations of the IDOL 
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gene lower plasma cholesterol levels (72), whereas polymorphisms in the gene region are 
associated with elevated plasma cholesterol in humans (73).  
 
IDOL and LDLR 
Liver X receptor (LXR) is a nuclear receptor which regulates IDOL transcriptionally. Upon 
activation, LXR/retinoid X receptor (RXR) heterodimers bind to the promoter region of 
IDOL gene and regulate its function (74). Oxysterols work as ligands for LXRs (LXRα and 
LXRβ) and activate them (75). LXR activation up-regulates IDOL expression in the cells 
independent of clathrin-mediated endocytosis which then ubiquitinates LDLR by E3 
ubiquitin ligase and causes multi-vesicular body-mediated lysosomal degradation of the 
LDLR (Fig 5) (74-77).  
 
 
Fig 5: Degradation of LDLR by IDOL 
 
IDOL is found in various organs such as liver, intestine, spleen and adrenal gland in humans 
(76, 82, 83). However, studies have resolved IDOL as tissue and species-specific gene (84). 
It has been shown that LXR agonists enhance IDOL expression in peripheral tissue but not 
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in the liver in mice, whereas in cynomolgus monkeys, LXR agonist induces IDOL expression 
in liver and increases plasma LDL-C (84). 
Additionally, IDOL may ubiquitinate and promote the degradation of other LDLR family 
members, such as very low-density lipoprotein receptor (VLDLR) and ApoE receptor 2 
(ApoER2) (78, 79). 
1.7   Hormonal regulation of cholesterol metabolism 
Hormones are signaling molecules mainly secreted by endocrine glands (Fig 6). A large 
number of hormones may regulate cholesterol and bile metabolism. In this study, we focused 
on three hormones, estrogen, testosterone, and ACTH, which have previously been reported to 
influence cholesterol metabolism.  
 
 
Fig 6: Hormone producing glands in human (male and females) 
 
Estrogen 
Estrogen is a female sex hormone and important for reproduction. In females, estrogen is 
produced by the ovaries upon stimulation by luteinizing hormone (LH) and follicle 
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stimulating hormone FSH). Three main natural estrogens are found in females, estrone (E1), 
estradiol (E2), and estriol (E3). E2 is the most important sex hormone in women and is 
predominant during fertile years. The plasma level of E3 increases following menopause.  
Estetrol (E4), the fourth type of estrogen is only produced during pregnancy. Estrogen has a 
key role in the menstruation cycle. The level of estrogen reaches its peak at the ovulation 
phase and is then reduced during the follicular phase and luteal phase. Estrogen binds to 
estrogen receptors (ERs) located in the nucleus and at the cell membrane, and regulate 
various cellular functions (80).  
It has been reported that elevated estrogen levels reduce LDL-C, PCSK9, and Lp(a) (6, 81) 
while increasing HDL-C and ApoA1 (82). In addition, estrogen influences GH pathway. 
Moreover, circulating LDL-C and PCSK9 are lower in pre-menopausal women and increase 
after menopause (63), presumably due to the decrease in estrogen level. However, whether 
changes in the endogenous estrogen levels such as during the menstrual cycle influence LDL-
C and PCSK9 in females is not clear. 
Testosterone 
Testosterone is the primary male sex hormone, which maintains the reproduction function in 
males. Low levels of testosterone are found in females with certain diseases such as 
polycystic ovarian disease (PCOD) (83). Studies have claimed that testosterone may regulate 
lipoproteins (84). However, little is known about the effects of testosterone on cholesterol 
and bile acid metabolism. One study has shown that testosterone treatment reduces LDL-C 
by reducing PCSK9 in pigs (85). In contrast, no notable correlation was found between 
testosterone and PCSK9 in healthy males (86). Whether pharmacological doses of 
testosterone regulate cholesterol and bile acid metabolism is yet to be clear. 
ACTH 
ACTH is produced and secreted by the anterior pituitary gland (87). It is an important 
component of the hypothalamic-pituitary-adrenal axis and produced in response to stress 
(88). ACTH acts as a ligand for ACTH receptors that are predominantly found in the adrenal 
cortex. ACTH induces secretion of glucocorticoid, mineralocorticoid and androgenic steroids 
from the adrenal cortex, a cellular process called steroidogenesis. During stress, ACTH up-
regulates adrenal lipoprotein uptake by inducing cellular receptors such as LDLR and SRB1. 
Cholesterol within the lipoproteins thus serves as the precursor for steroid production.  
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Studies in rodents have previously shown that elevated ACTH levels increase plasma 
cholesterol by reducing hepatic LDLR numbers without changing the mRNA levels (3), 
indicating post-transcriptional regulation of LDLR upon ACTH exposure. It has been 
demonstrated that these effects are abolished in LDLR-/- mice (3), clarifying the importance 
of the LDLR for the development of hypercholesterolemia. However, whether PCSK9 or 
IDOL may post-transcriptionally regulate LDLR during prolonged stress is unknown.  
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2. AIMS  
Specific aims for papers 1-4 were: 
I. To investigate whether physiological changes in estrogen levels during the menstrual 
cycle and the menopause influence circulating PCSK9 and LDL-C. 
 
II. To examine the effects of testosterone treatment of healthy males on circulating PCSK9 
and on bile acid and cholesterol metabolism. 
 
III. To study the possible underlying mechanisms behind post-transcriptional regulation of 
hepatic LDLRs during ACTH treatment. 
 
IV. To examine the effects of CDCA, a natural FXR agonist, on lipoprotein metabolism. 
  
  15 
3. MATERIALS AND METHODS  
A general description of animals, human subjects, different study designs and methods used 
in this thesis are described below. Detailed information about each study is present in the 
individual papers. All participants in human studies had given informed written consent to 
participate in the studies, which had been approved by the Ethics Committee of Karolinska 
Institutet and Karolinska institutional Animal Care and Use Committee approved the animal 
experiments. 
3.1   Animals, human subjects, and study design 
Paper 1: Serum samples of 395 subjects (206 females and 189 males) were available for 
analysis from a previously described cohort of 435 healthy volunteers (89). Subjects had been 
excluded if they had a previous history of CHD, type 2 diabetes or dyslipidemia. Females 
taking hormonal therapy, or contraceptive pills were also excluded from the study. Overnight 
fasting blood samples were collected. Serum was prepared by centrifugation. Serum samples 
were stored at -80ºC.  
Paper 2: From a previously described study (90), plasma samples from 25 healthy male 
volunteers who were given 250mg (dose 1) or 500mg (dose 2) of intramuscular testosterone 
enanthate (Testoviron® Depot) were available for analysis. Fasting blood samples were 
collected prior to testosterone administration (Day 0), and 4 (Day 4) and 14 days (Day 14) after 
testosterone administration.  
Paper 3: Two sets of animal experiment were performed. In the first, 36 male Sprague Dawley 
rats (B&K Universal AB, Sollentuna, Sweden) were used. Animals were injected 
subcutaneously with Tetracosactide (ACTH) (Synacthen depot, Ciba-Geigy, Horsham, Sussex, 
UK), or 0.9% NaCl (controls) at 0900 h and 1600 h for different time points (3 hours to 92 
hours). In second set of experiments, 16 male wild-type (B6129SF2/J) and 16 PCSK9-/- 
(B6;129S6-Pcsk9tm1Jdh/J) mice were used. All mice were from Jackson Laboratory (Bar 
Harbor, ME, USA). Mice were treated subcutaneously with either Tetracosactide (Synacthen 
depot, Ciba-Geigy, Horsham, Sussex, UK), or 0.9% NaCl twice a day for 75h. At the end of 
the experiments, animals were anesthetized, bled by cardiac puncture, and killed by cervical 
dislocation. Serum was separated and stored at -80ºC. Livers and adrenal glands were collected 
in liquid nitrogen and stored at -80ºC. 
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Paper 4: Two human studies were performed  
In experiment 1, autologous 125I-LDL was injected in 12 males, and clearance of LDL from 
blood plasma was characterized during acute and long-term treatment with CDCA. Blood 
(~100 ml) was drawn in the fasting state for preparation of LDL and subsequent iodination 
with 125I. 125I-LDL was injected within 5 days of labeling, and repeated blood samples were 
drawn for 2-3 weeks. When the 125I-radioactivity curve was in the log-linear phase, about 10-
14 days after injection, CDCA administration was initiated. In 5 patients, the acute effect (6-7 
days) of CDCA administration was studied. After short and long-term treatment, the fractional 
catabolic rate (FCR) of 125I-LDL was calculated both from plasma curve and from plasma/urine 
ratio.  
In experiment 2, 7 gallstone patients scheduled for surgery were studied. Serum was collected 
before and after 3 weeks of CDCA treatment. 15 untreated gallstone patients served as controls. 
A liver biopsy was taken during surgery. 
3.2   Serum analysis 
Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA for human serum: Commercially available ELISA kits were used to measure PCSK9 
(Circulex; CycLex, Japan), insulin (Ultra-sensitive human insulin ELISA kits, Marcodia, 
Sweden), FGF19 (Quantikine, R&D Systems, Minneapolis, MN, USA), β-estradiol 
(Demeditec diagnostics GmbH, Germany), follicle stimulating hormone (Demeditec 
diagnostics GmbH, Germany).  All the ELISA kits were used according to manufacturer´s 
instruction.  
ELISA for animal serum: Rat serum PCSK9 was assayed by mouse/rat PCSAK9 ELISA kit 
from Circulex, Japan and mice serum PCSK9 was analyzed by mouse PCSK9 immunoassay 
kit from R&D Systems Inc., Minneapolis, USA as described by manufacturers. 
Serum cholesterol, Triglyceride and glucose 
For paper 1 and 4, total and HDL-C, TG, and glucose were determined using standard clinical 
chemistry techniques. LDL-C was assessed according to Friedewald et al (91).  
For paper 2 and 3, total cholesterol (Total-C) and total TG (Total-TG) were assayed with a 
commercial kit (Roche Diagnostics GmbH, Mannheim, Germany).  Cholesterol and TG serum 
lipoprotein (VLDL, LDL and HDL) profiles were analyzed by fast performance liquid 
chromatography (FPLC) (89).   
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Bile acid synthesis 
Serum concentration of 7α-Hydroxy-4-cholesten-3-one (C4), a marker of bile acid synthesis, 
was determined by high-performance liquid chromatography (HPLC) using 7b-hydroxy-4-
cholesten-3-one as internal standard. The values were normalized for total cholesterol (C4/c) 
(32). 
Cholesterol synthesis 
Unesterified lathosterol, a marker of cholesterol synthesis, was assayed by isotope dilution 
mass spectrometry after the addition of deuterium-labeled internal standard as described 
previously. Lathosterol levels were corrected for total cholesterol (lathosterol ⁄c) (89). 
Bile acids in serum 
Serum bile acids (BA) including total bile acid (TBA), unconjugated and conjugated cholic 
acid (CA), Deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ursodeoxicholic acid 
(UDCA) and lithocholic acid (LCA) were determined by liquid chromatography tandem mass 
spectrometry using deuterium-labelled BA standards (92).  
Serum apolipoproteins and Lipoprotein(a) (Lp(a)) 
Serum apolipoproteins such as apolipoprotein A1 (apoAI) (Ref No. KAI-002), apolipoprotein 
A11 (apoAII) (Ref No. KAI-003), apolipoprotein B (apoB) (Ref No. KAI-004), apolipoprotein 
CII (apoCII) (Ref No. KAI-005), apolipoprotein CIII (apoCIII) (Ref No. KAI-006) and 
apolipoprotein E (apoE) (Ref No. KAI-007) were analyzed according to manufacturer’s 
instruction by using immunoturbidimetric assay kits from Kamiya Biomedical Company, 
Seattle, USA (93). TruLab Lp(a) kit (Ref no. 598309910046; Diasys, Germany) was used to 
measured serum Lp(a) (93). All the kits were analyzed by Respons ® 910 analyzer from 
Diasys, Germany.  
3.3   Tissue analysis 
Liver TG and cholesterol 
Liver lipid was extracted as described by Folch et al. TG content in liver homogenates was 
detected by colorimetric analysis using a commercial kit from Roche Diagnostics GmbH, 
Mannheim, Germany. Liver cholesterol contents were determined by gas chromatography-
mass spectroscopy (GC-MS) (94).  
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H&E staining 
Small pieces of livers were saved in 4% PFA overnight and then in 70% ethanol until the 
preparation of paraffin-embedded block. Tissue sections were prepared and stained with 
Hematoxylin and eosin (H&E) stain for histology.   
Activity assay and LDLR binding assay 
Cholesterol 7α-hydroxylase (CYP7A1) and 3-hydroxy-3-methylglutaryl CoA reductase 
(HMGCoAR) activities in isolated microsomal fractions were analyzed as described (95, 96). 
Specific heparin-sensitive LDLR binding was determined in liver homogenates as described 
(43, 97). 
3.4   Western blot  
Membrane proteins were prepared as described (6) and added to Laemmli sample buffer (Bio-
Rad Laboratories) together with 50mM dithiothreitol (DDT) and then separated on 8% SDS-
PAGE gels. The proteins were electrotransferred to nitrocellulose. The membranes were 
blocked with 5% nonfat dried milk, dissolved in TBST with 1% tween 20. The membranes 
were then incubated with corresponding primary antibodies (1:1000 dilution) overnight. After 
wash, membranes were incubated with HRP-conjugated secondary antibodies for 1h and 
washed and then analyzed by CCD camera and quantified by a LAS 1000 plus imager and 
Multi Gauge software Science Lab 2005 version 3.1 (Fuji Photo). The quantified bands are 
expressed as arbitrary units. LDLR polyclonal antibody (ab30532) was from Abcam and 
PCSK9 polyclonal antibody (10007185) from Cayman Chemicals (Ann Arbor, MI) were used 
for rat samples, and anti-PCSK9 antibody (ab125251) from Abcam was used for mouse 
samples. IDOL polyclonal antibody (LS-C119933) was from Lifespan biosciences, Inc. Anti-
actin polyclonal antibody (ab8227) was used as loading control. Goat-anti-rabbit HRP 
conjugated secondary antibody (1858415) was from Pierce.  
3.5   Quantitative real-time PCR 
Total RNA was extracted from frozen liver samples using Trizol reagent (Invitrogen, Carlsbad, 
CA). cDNA was synthesized using random-hexamer priming and Omniscript (QIAGEN, 
Valencia, CA). Quantitative real-time PCR was performed in an ABI Prism 7700 sequence 
detection system (ABI, Foster City, CA) using SYBR Green. 18S, LDLR, PCSK9, IDOL, 
SREBP-2 and HMG COAR genes expression were examined by using primers as mention in 
paper 3.  
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3.6   Statistics 
The differences within multiple groups was compared by one-way ANOVA following Tukey’s 
post hoc comparisons test and differences between two groups were compared by paired or 
non-paired student t-test. GraphPad Prism version 5 (GraphPad Software, SanDiego, CA) was 
used for all the comparisons. (Details are referred to in individual papers). 
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4. RESULTS AND COMMENTS 
4.1 Paper 1 
Physiological changes in endogenous estrogen levels in females are linked to serum 
PCSK9 levels and LDL-C 
We aimed to evaluate whether the natural changes of endogenous E2 that occur during aging 
as well as during the different phases of the menstrual cycle are related to changes in the 
circulating levels of PCSK9 and LDL-C. In this study, we demonstrate the possible 
underlying mechanism behind the variation in LDL-C levels during different phases of 
menstruation cycle and show a possible reason for elevated levels of plasma PCSK9 in post-
menopausal women. 
 In a Swedish cohort, PCSK9 levels ranged between 113 and 831 ng/mL, with a mean 
concentration of 290ng/ml. Mean PCSK9 levels in males (275 ng/mL) was lower than in 
females (304 ng/mL; P <0.05). In females, plasma PCSK9 increased in parallel with LDL-C 
with increasing age, which was not observed in males. In males, there was no significant 
change of PCSK9 levels with increasing age, although plasma cholesterol increased similar 
to what was seen in females. 
Impact of menopausal status on plasma PCSK9 level in females 
To better understand the relation between age and PCSK9 level in females, we divided them 
into two groups; pre-menopausal (< 50 years) and post-menopausal women (> 50 years). We 
considered 50 years as the average age for menopause in Swedish healthy female cohort (19). 
In agreement with previous studies, our results also show that plasma PCSK9 in 
postmenopausal women (333ng/mL) was significantly higher compared to pre-menopausal 
women (272 ng/mL). In males, PCSK9 levels do not change with age. These results indicate 
a possible role of estrogen for plasma PCSK9 in females.  
PCSK9 and menstrual cycle 
To further understand the distribution of PCSK9 and cholesterol during menstruation cycle 
and their relation with E2, we sorted out pre-menopausal females according to their 
menstruation phases based on their reported last menstruation date.  They were divided into 
three phases, follicular phase (days 1-11), ovulation phase (days 12-18) and luteal phase 
(days 13-32) (20). The E2 levels were significantly lower in the follicular phase and highest 
in those in the ovulation phase whereas, an average level of Serum E2 found in their luteal 
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phase. We found a noticeable reduction of PCSK9 in the ovulation phase and in the luteal 
phase as compared to the follicular phase. Interestingly, LDL-C and total-C followed the 
same trend as PCSK9 (Fig 7A-D).  
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Fig 7: Changes in A) E2, B) PCSK9, C) LDL-C and D) Total-C during menstruation cycle 
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4.2 Paper II 
Testosterone reduces PCSK9 in healthy males while cholesterol and bile acid syntheses 
are unaltered 
Paper 1 demonstrates that plasma PCSK9 levels increase with age in females but not in males 
(102). The reduction in endogenous estrogen levels with age in females may partly explain 
this. However, on the other hand, studies have shown that cholesterol and bile acid synthesis 
are higher in males than in females (89, 98-100). Whether testosterone has any effects on 
these parameters is unclear. We tested the hypothesis that testosterone will induce bile acid 
and cholesterol syntheses and PCSK9 levels in normal males.   
Effects of testosterone on cholesterol and bile acid synthesis 
Despite marked increases of serum testosterone, we did not observe any changes in serum 
lathosterol, the marker of cholesterol synthesis, or C4c, an indicator of bile acid synthesis, 
indicating that testosterone was without effect on cholesterol synthesis or bile acid 
production. Serum total and individual bile acids were unchanged after 4 days of treatment 
but tended to increase on day 14 following the highest dose given, while there was no 
consistent pattern regarding conjugated or unconjugated cholic, chenodeoxycholic, 
deoxycholic, ursodeoxycholic or lithocholic acids. Also, the level of FGF19, reflecting bile 
acid interaction with intestinal FXR, was not altered.  
Testosterone and serum PCSK9 and lipoproteins 
Four days after injection, circulating PCSK9 levels were significantly reduced. Testosterone 
did not alter plasma total cholesterol or triglycerides. A trend for increased total triglyceride 
levels was observed 2 weeks after injection, however.  
Additionally, there were no significant changes observed in VLDL-C, LDL-C or HDL-C 
levels on day 4. However, VLDL-C levels were increased on day 14 whereas LDL-C and 
HDL-C levels were decreased.   
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4.3 Paper III 
Post-transcriptional regulation of LDLRs by PCSK9 and/or by IDOL 
In papers 1 and 2, we demonstrated that hormones such as estrogen and testosterone could 
regulate PCSK9. In paper 3, we hypothesized that LDLRs in the adrenals and the liver might 
be subject to regulation by PCSK9 or IDOL upon ACTH treatment. 
Post-transcriptional regulation of adrenal LDLR numbers by IDOL in response to 
ACTH 
ACTH treatment is well known to increase LDLR mRNA levels in the adrenal gland. We 
hypothesized that posttranscriptional regulation of LDLRs may also occur through lowering 
of PCSK9 and/or IDOL in this situation. PCSK9 mRNA and protein were both undetectable 
in the adrenal gland. In contrast, adrenal IDOL was detected and shown to be suppressed 
during such treatment, both at mRNA and protein levels, indicating the involvement of IDOL 
in the regulation of LDLRs in the adrenal gland. These effects were more pronounced in rats 
than in WT mice, but were not observed in PCSK9-/- mice PCSK9.  
Post-transcriptional regulation of hepatic LDLRs by PCSK9 following ACTH 
 
In rat experiments, it was shown that the downregulation of hepatic LDLRs following ACTH 
treatment was accompanied by increased levels of PCSK9 protein, but not its mRNA, levels. 
In contrast, hepatic IDOL expression was unchanged. 
To study this further, PCSK9-/- and WT mice were treated with and without ACTH. Similar 
to what was seen in rats, ACTH treatment increased serum total cholesterol and LDL-C and 
HDL-C in WT mice, but this was not seen in PCSK9-/- mice. While LDLR mRNA was 
unchanged during treatment, its protein expression was reduced 50% in WT mice, there was 
no difference in either in PCSK9-/- mice during ACTH exposure. In WT mice, PCSK9 protein 
was increased 2-fold by ACTH treatment, whereas both mRNA and protein levels were 
undetectable in PCSK9-/- mice.  
In addition, when we assayed PCSK9 protein in livers from adrenalectomized (ADX) rats 
treated with ACTH and their untreated controls, this response was abolished, indicating an 
adrenal gland dependent hepatic response of ACTH.  
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4.4 Paper IV 
CDCA increases plasma LDL-C by reducing hepatic LDL-C clearance but 
concomitantly reduces plasma PCSK9  
Increased plasma LDL-C levels have been observed during CDCA treatment in humans (101, 
102). We here explored possible mechanisms behind this effect.  
Three weeks of treatment with CDCA was associated with a small but significant increase in 
total plasma cholesterol (7%, p <0.05) and LDL-C (10%, p< 0.05) (Fig 8A). Turnover studies 
utilizing autologous125I-LDL showed that, although the total amount of apoB containing 
lipoproteins was unchanged, the FCR of apoB in LDL was significantly reduced (Fig 8B). 
The onset of the FCR reduction was seen already within one day of CDCA treatment (Fig 
8C).  
 
 
Fig 8: Changes in lipoproteins (A) and FCR, calculated from plasma (B) during 3 weeks of 
CDCA treatment. Acute responses of CDCA on FCR (C). 
A
B
C
  25 
To determine if the hepatic LDL receptor binding activity was altered upon CDCA treatment, 
the heparin-sensitive binding of 125I-LDL to liver homogenates was determined from liver 
biopsies. CDCA treatment was associated with a 20% lower 125I-LDL binding (P=0.09), 
indicating a reduced number of LDLRs number in liver (Fig 9A). An important finding was 
that CDCA treatment significantly reduced circulating PCSK9 in these subjects (Fig 9B).  
 
 
Fig 9: LDLR binding activity decreases 20% (A) together with the reduction of circulating 
PCSK9 (B). 
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5. DISCUSSION AND FUTURE PROSPECTIVE 
Studies from the last two decades have established that PCSK9 is an important regulator of 
cholesterol metabolism and a highly promising drug target for reducing hypercholesterolemia. 
Recently FDA approved PCSK9 inhibitors for the treatment of hyperlipidemia. Understanding 
how the expression of PCSK9 may be modulated is therefore of major importance, both from 
physiological and pharmacological aspects. In this thesis, findings of how alterations in 
estrogen and testosterone levels, induction of adrenal corticosteroid production and treatment 
with CDCA modulate PCSK9 are reported. 
5.1 Estrogen and PCSK9 
Estrogen has several physiological functions. Studies have shown that increased endogenous 
estrogen levels are associated with decreased plasma cholesterol concomitantly with reduced 
PCSK9 levels in humans. However, in a population study, subjects on estrogen therapy did not 
show any notable changes in PCSK9 levels (63) which may indicate different effects of 
endogenous and exogenous estrogen on lipid metabolism as previously noticed (103). In 
addition, estrogen treatment has been reported to reduce hepatic PCSK9 and thereby plasma 
LDL-C in rats (6).  
PCSK9 correlates negatively with the estrogen level in healthy women and increases markedly 
after menopause, suggesting an influence of endogenous estrogen levels on PCSK9 levels in 
females. The relation of LDL-C and PCSK9 to endogenous estrogen levels led us to 
hypothesize that the changes in endogenous estrogen levels during the menstruation cycle 
could influence PCSK9 and thus LDL-C in females. We here demonstrate in paper 1 that the 
estrous cycle strongly relates to PCSK9 levels in menstruating women.  The changes in 
estrogen levels during menstruation cycles are likely to influence PCSK9 and thereby LDL-C 
levels as reported in normal women. However, a Chinese population study did not demonstrate 
any effects on PCSK9 levels during the menstruation cycle. The authors also reported that 
estrogen treatment at a physiological dose failed to reduce PCSK9 in human hepatocytes. In 
contrast, it was shown that the up-regulation of LDLRs by estrogen in human hepatocarcinoma 
HuH7 cells is dependent on PCSK9 (104). Our study indicates that changes in endogenous 
estrogen levels during menstruation or menopause could influence PCSK9 in females.  
To further advance knowledge, other situations with varying estrogen levels in humans should 
be explored. Tentative future studies could include characterization of lipoprotein and PCSK9 
levels during normal pregnancy or after sex reassignment surgery.
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5.2 Testosterone and PCSK9 
Little information is available on the effects of testosterone on PCSK9. It has been reported 
that testosterone levels in healthy males do not correlate with PCSK9 or with LDL-C (86). 
Moreover, testosterone replacement therapy (TRT) in hypogonadal men was unable to alter 
LDL-C and PCSK9 levels (86). The effects of testosterone treatment at high doses on PCSK9 
in healthy males had not been studied, however.  In paper 2, we showed that pharmacological 
doses of testosterone reduce circulating PCSK9 in healthy males. Similar results were found in 
pigs where hepatic and circulating PCSK9 expression was induced in pigs with castration-
induced testosterone deficiency that was restored by TRT (105). Interestingly, we observed 
that the changes in PCSK9 levels during treatment did not correspond to the plasma LDL-C in 
these subjects. It is somewhat difficult to explain why the reduction of PCSK9 following 
testosterone is not associated with any reduction of LDL cholesterol.  There are however 
situations where changes in serum LDL cholesterol and PCSK9 do not show the expected 
covariation, as we found in paper 4. Additionally, an increase in VLDL-C together with 
suppressed plasma LDL-C and HDL-C levels were observed 2 weeks after treatment. Such late 
changes in lipoproteins following testosterone treatment have indeed been reported previously 
(84, 106). Increased VLDL production and inhibition of hepatic lipase activity (106, 107) may 
be the possible explanations behind this accumulation of VLDL remnants and reduction in 
LDL-C and HDL-C levels.   
Further animal studies would be of clear interest in order to understand in more detail the 
underlying mechanism.  
5.3 Testosterone and gender dependent cholesterol and bile acid synthesis   
Studies have shown that in human, bile acid and cholesterol production (89) and the plasma 
bile acid level (100) are higher in males than in females. Studies in castrated male mice have 
indicated that androsterone, the metabolically active product of testosterone, may be a 
Farnesoid X Receptor (FXR) ligand inducing expression of the FXR target gene small 
heterodimer partner (SHP) and thus could suppress bile acid synthesis by inhibiting 
CYP7A1(108). We, therefore, hypothesized that testosterone has a role in these gender-related 
differences.  
However, it is clear from this study that testosterone has no major effects on cholesterol and 
bile acid synthesis in humans. Other mechanisms for this important gender difference must, 
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therefore, be sought. The fact that there are major species differences regarding the influence 
of sex on cholesterol metabolism makes it difficult to explore this question in animal models. 
5.4 ACTH and PCSK9 
Effects of ACTH on cholesterol metabolism have been reported previously. It was clear from 
a previous study that during prolonged ACTH stress, plasma cholesterol was increased in rats 
and mice through suppression of hepatic LDLR protein levels. In addition, this effect was 
absent in ADX rats, indicating an adrenal gland dependent effect of ACTH on cholesterol 
metabolism (3). However, LDLR mRNA levels were unaltered during ACTH exposure (3), 
suggesting possible post-transcriptional regulation of LDLRs by ACTH, mediated by the 
adrenal glands. We demonstrated in paper 3 that PCSK9 post-transcriptionally reduces hepatic 
LDLR numbers, thereby increasing plasma cholesterol. Additionally, we found that PCSK9 
expression in liver was unaffected in ADX rats receiving ACTH, further demonstrating that 
the adrenal glands are critically involved in mediating the effects of ACTH on the liver (3). We 
speculate that the adrenal glands signal to other tissues including the liver by an unknown 
"factor X" to decrease lipoprotein clearance thereby elevating the cholesterol level in the blood 
to secure the supply of cholesterol in adrenals for corticosteroid production.  
Since the protein but not the mRNA levels of PCSK9 were increased, this indicates that there 
is possible posttranscriptional regulation of PCSK9 itself (109). An unchanged level of 
circulating PCSK9 during ACTH treatment strengthens the concept that PCSK9 itself may be 
regulated post-transcriptionally upon ACTH treatment. This also highlights a possible 
involvement of intracellular variation of hepatic PCSK9, which may be important for the 
expression of the LDLR, as reported in other studies (110). However, in contrast to liver, the 
expression of PCSK9 in adrenal glands is negligible, indicating the involvement of other 
substitutional mechanisms for regulating LDLR in the adrenal glands. 
In the future, we would like to identify "factor X" by utilizing cross circulation experiments 
and with proteomic, lipidomic and metabolomics screening procedures. The intracellular 
location of increased PCSK9 molecules in the hepatocyte following ACTH treatment and their 
morphological relation to the intracellular LDLR pathway would be another important aspect 
to consider. 
5.5 ACTH and IDOL 
IDOL, the recently identified regulator of cholesterol metabolism, has been reported to regulate 
LDLR post-transcriptionally. However, we have not noticed any obvious effects of ACTH on 
hepatic IDOL. However, IDOL seems to regulate LDLR in peripheral tissues, as we found in 
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adrenal glands. IDOL mRNA and protein expression are downregulated during ACTH 
exposure, which may partly explain the induced LDLR number in adrenal glands during 
prolonged stress. Future studies on IDOL-/- mice or rats may also be of interest. 
5.6 CDCA, lipoproteins and PCSK9 
In paper 4, we studied why CDCA, a natural FXR agonist (111, 112), causes a moderate 
increase in plasma LDL-C in humans. We found that LDLRs are downregulated following 
CDCA treatment, thereby diminishing the clearance of LDL particles. However, studies have 
shown a moderate 10% induction of plasma LDL-C (101, 102). Our results also confirm that 
LDL-C increases about 6% just after initiation of treatment and about 13% after 3 weeks of 
treatment.  
We found that plasma PCSK9 is significantly reduced following CDCA treatment, which could 
be expected as the transcription of PCSK9 is known to be regulated by SREBP2. Thus, CDCA 
has been shown to suppress PCSK9 mRNA and protein expression in human hepatocytes (113, 
114). Additionally, CDCA reduces LDL production possibly by reducing VLDL production 
(115, 116). The reductions of PCSK9 levels and LDL production might, therefore, 
counterbalance the reduced clearance of plasma LDL-C. Additionally, we found that CDCA 
lowers Lp(a).  
Limited information is available so far about the effects of FXR agonists on lipoproteins or 
apolipoproteins (117). Moreover, it is important to consider that many early trials have reported 
increases in LDL-C in response to synthetic FXR agonists (118, 119). In the FLINT study, 
plasma LDL-C increased markedly during treatment with obeticholic acid, a bile acid analog 
and a strong FXR agonist (120). Studies on healthy subjects have also shown that obeticholic 
acid treatment resulted in larger LDL particles in the plasma (121).  
Therefore, it will be important to perform more detailed studies on lipoprotein metabolism 
following such therapy and also to understand further the influences of various synthetic FXR 
agonists regarding their effects on PCSK9, apoCIII and Lp(a) as seen in response to CDCA 
treatment in our study. 
5.7 Relevance of PCSK9 regulation 
In summary, this work has advanced the knowledge about the regulators of PCSK9 that 
modulate circulating and/or intracellular PCSK9, and thereby cholesterol metabolism. Both 
male and female sex hormones were found to decrease circulating PCSK9, indicating that this 
LDLR-modulator is under the hormonal control. In addition to hormones, CDCA, a primary 
bile acid, and natural FXR agonist, reduces circulating PCSK9 levels in humans. Furthermore, 
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this work indicates that intracellular PCSK9 post-transcriptionally regulates hepatic LDLRs 
and induces plasma cholesterol during prolonged stress induced by ACTH. However, these 
effects of PCSK9 are adrenal gland dependent, indicating that the adrenal glands signal to liver 
to decrease lipoprotein clearance thereby elevating the cholesterol level in the blood to secure 
the supply of cholesterol in adrenals for corticosteroid production. It would be interesting to 
investigate this signaling factor that controls cholesterol metabolism during stress.  
The advancement in the knowledge about these PCSK9 regulators should eventually be 
advantageous for the treatment and prevention of human diseases such as atherosclerosis and 
dyslipidemia.   
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6. CONCLUSIONS 
The following conclusions can be drawn from the above studies.  
1) Circulating PCSK9 increases with age in females but not in males. PCSK9 is higher in 
post-menopausal females than in pre-menopausal females or in males. Physiological 
changes in estrogen levels during menstruation influence circulating PCSK9 levels and 
the level of plasma LDL-C.  
 
2) Testosterone at pharmacological doses reduces circulating PCSK9 in healthy males. 
However, the reduction of PCSK9 following this treatment does not alter LDL-C levels. 
In addition, known human gender differences in bile acid and cholesterol synthesis are 
not likely explained by testosterone. 
 
3) ACTH stimulates LDLR expression in the adrenal where suppressed IDOL levels may 
contribute. Following ACTH, PCSK9 post-transcriptionally suppresses hepatic LDLRs 
during prolonged, thereby increasing plasma cholesterol. These effects are adrenal 
gland dependent, and suggest the presence of a mechanism for shunting lipoprotein 
cholesterol to the adrenals in situations of prolonged stress. 
 
4) The increase in plasma cholesterol during CDCA treatment is due to reduced plasma 
clearance of LDL-C via hepatic LDLRs. Concomitantly, CDCA reduces circulating 
PCSK9 which may counterbalance its effect on hepatic LDLRs and on plasma LDL-C. 
CDCA also down-regulates Lp(a) and ApoCIII in humans.  
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